Recent advances in molecular profiling have identified new cancer drug targets and prognostic markers. This course will review current efforts to apply state-of-the-art genetic profiling to guide patient care. Topics will include a discussion of the optimal use of genetic testing in the clinical management of cancer patients and recent advances in the development of molecular signatures that predict for sensitivity to targeted kinase inhibitors and immunotherapies.
This conference should be of value to MD’s, PhD’s, DO’s, PA’s, NP’s, RN’s, allied medical professionals.
Memorial Sloan Kettering Cancer Center designates this educational activity for a maximum of 14AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.